Workflow
港股通医药
icon
Search documents
医药板块领涨港股,恒生创新药ETF(159316)半日获1100万份净申购
Mei Ri Jing Ji Xin Wen· 2025-08-21 05:57
Core Viewpoint - The pharmaceutical and healthcare indices in the Chinese stock market have shown positive performance, with significant inflows into innovative drug ETFs, indicating a growing interest in the sector [1][2]. Group 1: Index Performance - The CSI 300 Pharmaceutical and Healthcare Index increased by 1.2% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index rose by 1.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Biotechnology Theme Index both saw a rise of 0.7% [1]. - The CSI Innovative Drug Industry Index experienced a slight increase of 0.01% [1]. Group 2: ETF Activity - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of 11 million units in the first half of the day, bringing its total size to over 1.5 billion yuan, a historical high [1]. - The index tracked by the Hang Seng Innovative Drug ETF focuses on leading innovative drug companies in the Hong Kong stock market, comprising no more than 40 stocks involved in innovative drug research, development, and production [2]. - The rolling price-to-earnings ratio for the Hang Seng Innovative Drug Index is currently at 56.2 times [2]. Group 3: Valuation Metrics - The rolling price-to-earnings ratio for the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Comprehensive Index stands at 30.4 times, with a valuation percentile of 48.1% since 2017 [2]. - The rolling price-to-earnings ratio for the CSI Innovative Drug Industry Index is not specified, but it focuses on A-share innovative drug leaders, comprising no more than 50 stocks involved in innovative drug research and development [2].